Vanguard Capital Management’s VistaGen Therapeutics VTGN Stock Holding History
Bought
Maintained
Sold
Other funds holding VTGN
Vanguard Capital Management's VTGN Position: Q3 2026 in Review
Vanguard Capital Management held its VistaGen Therapeutics (VTGN) position steady in Q3 2026 at 1,574,200 shares worth $485K. The position accounts for ﹤0.01% of the portfolio, ranked #3683.
Vanguard Capital Management first reported a position in VTGN in Q1 2026 and has held it in 3 quarters since. The position peaked at $900K in Q1 2026. 42 funds tracked by Wall St. Rank hold VTGN as of Q3 2026.
- Vanguard Capital Management held 1,574,200 shares of VistaGen Therapeutics worth $485K as of Q3 2026.
- Vanguard Capital Management left its VistaGen Therapeutics share count unchanged in Q3 2026.
- VistaGen Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3683 holding.
- Vanguard Capital Management first reported a position in VistaGen Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's VistaGen Therapeutics position peaked at $900K in Q1 2026.
- 42 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.